We are almost there ...
Zydus Lifesciences pulled up by FDA over quality-control issues
The US health regulator, in a letter to the pharma company, accuses it of violating good manufacturing practices at its Vadodara plant.
15 September, 2024•2 min
0
15 September, 2024•2 min
0
Subscribe to read this story
We publish over 500 original, detailed stories every year on startups, corporates, stock markets and economic current affairs.
Limited time offer $125 $99 for 1 year
SUBSCRIBE
Already have an account? Sign In
More in Business
Business
Blaming FII selloff for the market fall is lazy, says Shankar Sharma
The veteran investor goes over the recent stock market crash with a fine-tooth comb, analysing whether the market has bottomed out or a bear run is around the corner.
You may also like
Internet
Why is Swiggy catching flak for its latest quick-delivery promise?
The food and grocery delivery company’s idea of providing prescription drugs in 10 minutes is facing resistance from traditional pharma players.
Business
Natco just can’t kick its high-risk, high-gain game plan
CEO Rajeev Nannapaneni’s oft-used strategy of mounting patent challenges in the US got the pharma company its latest blockbuster Revlimid. But what after sales fall off a cliff?
Business
KKR set to hit the jackpot with JB Chemicals and Pharma
The investment giant is rumoured to be eyeing an exit with a 5x return, having taken the drugmaker from obscurity to a billion-dollar bidding war.